NASDAQ | ETF
The fund is an actively-managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks ofU. S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 15.23% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 7.96% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 6.29% |
| NVS | Novartis AG ADR | Healthcare | Drug Manufacturers - General | 6.16% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 5.84% |
| AZN | AstraZeneca PLC ADR | Healthcare | Drug Manufacturers - General | 4.93% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 4.93% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 4.17% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 4.04% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 4.02% |
| ALKS | Alkermes Plc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.96% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 3.42% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 3.11% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 3.07% |
| IONS | Ionis Pharmaceuticals Inc | Healthcare | Biotechnology | 2.62% |
| GSK | GlaxoSmithKline PLC ADR | Healthcare | Drug Manufacturers - General | 2.37% |
| BCYC | Bicycle Therapeutics Ltd | Healthcare | Biotechnology | 1.84% |
| BEAM | Beam Therapeutics Inc | Healthcare | Biotechnology | 1.44% |
| NTLA | Intellia Therapeutics Inc | Healthcare | Biotechnology | 1.27% |
| REPL | Replimune Group Inc | Healthcare | Biotechnology | 0.97% |